Cetuximab
Salivary Gland Adenoid Cystic Carcinoma
Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Fox Chase Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01637194CT.gov Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer | — | Completed | — | — | — |
NCT00397384CT.gov Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | — | Completed | — | — | — |
NCT00101348CT.gov Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Salivary Gland Adenoid Cystic Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cetuximab (this asset) | Fox Chase Cancer Center | P1/2 | B · 62 |
| Irinotecan | National Cancer Institute (NCI) | P1/2 | B |
| Fludeoxyglucose | Sanjiv Sam Gambhir | P1/2 | CCC |
| (18F)FPPRGD2 | Sanjiv Sam Gambhir | P1/2 | CCC |
| Abi-007 | National Cancer Institute (NCI) | P1 | CC |
| 7-hydroxystaurosporine | National Cancer Institute (NCI) | P1 | CC |
| Carboplatin | National Cancer Institute (NCI) | P1 | CC |
| Trastuzumab | National Cancer Institute (NCI) | P1 | CC |
| Everolimus | Fox Chase Cancer Center | P1 | CC |
+3 more in the Salivary Gland Adenoid Cystic Carcinoma cohort
Other indications for Cetuximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colon Adenocarcinoma | — | P3 | BB · 70 |
| Rectal Carcinoma | — | P2 | BB · 69 |
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cetuximab in Salivary Gland Adenoid Cystic Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cetuximab-salivary-gland-adenoid-cystic-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →